Search the site

Start Stronger, Live Longer Resource Manual for Aboriginal Health Workers

This resource kit for Aboriginal health workers is an exciting milestone in the Rio Tinto Aboriginal Health partnership with The Kids Research Institute Australia

KAMS MOU

As part of the discussions with Kimberley Aboriginal Medical Service (KAMS) to establish the Broome site of the WAAHKN it has been agreed to establish...

Working Together Second Edition

This 2nd edition is intended for staff and students and all health practitioners working in areas that support Indigenous mental health and wellbeing.

Heritable and environmental determinants of hospitalisation for common childhood illnesses

We will leverage the unique Western Australian data linkage resources to undertake the definitive twin and sibling study of infection-related hospitalisation

GAMA project

This study investigated host gene expression in response to new HIV infection.

A diagnostic test for acute rheumatic fever (pilot study)

Currently there are no diagnostic tests for ARF, and no treatments targeting immune responses to improve disease outcomes.

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

A Phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infants (NeXXstep)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical

A Phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults (Quintet)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical